Endo International PLC (ENDP) Lifted to “Hold” at Zacks Investment Research
According to Zacks, “Endo’s top line should continue to benefit from robust performance of Xiaflex, sterile injectables and alternative dosages. Its efforts to prioritize R&D projects bode well. Endo recently entered into an agreement to return rights to Belbuca to BioDelivery. Endo expects to realize cost savings, achieve higher efficiency and improve operational focus of the U.S. Branded segment. It plans to focus on Xiaflex in the approved indications and the cellulite development program. Endo will also be concentrating on its pain portfolio products, including Opana ER and Percocet among others, which will be managed as mature brands. We are also pleased with Endo’s growth-by-acquisition strategy. However, both Branded and Generic segments are under pressure, which is concerning. Also, shares of Endo have underperformed that of the industry in the past one year. Continued pricing and competitive pressures remain major overhang on the shares.”
Other research analysts have also recently issued reports about the company. Guggenheim reiterated a buy rating and set a $35.00 price target on shares of Endo International PLC in a research report on Saturday, October 15th. Mizuho reiterated a buy rating and set a $29.00 price target on shares of Endo International PLC in a research report on Monday, September 19th. Citigroup Inc. reduced their price target on Endo International PLC from $40.00 to $25.00 and set a buy rating for the company in a research report on Friday, September 16th. JMP Securities reiterated a buy rating on shares of Endo International PLC in a research report on Friday, November 18th. Finally, Oppenheimer Holdings, Inc. reiterated a hold rating on shares of Endo International PLC in a research report on Tuesday, November 8th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of Buy and an average price target of $31.41.
Endo International PLC (NASDAQ:ENDP) traded down 3.497% during trading on Tuesday, hitting $13.385. The stock had a trading volume of 5,214,556 shares. The stock’s 50-day moving average is $16.16 and its 200-day moving average is $18.51. The stock’s market capitalization is $2.98 billion. Endo International PLC has a 52-week low of $12.56 and a 52-week high of $61.14.
Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Tuesday, November 8th. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.20. The company earned $894.30 million during the quarter, compared to analysts’ expectations of $862.47 million. Endo International PLC had a positive return on equity of 15.95% and a negative net margin of 3.32%. Endo International PLC’s quarterly revenue was up 18.6% on a year-over-year basis. During the same period last year, the business earned $1.02 earnings per share. On average, analysts predict that Endo International PLC will post $4.59 earnings per share for the current fiscal year.
In related news, Director Roger H. Kimmel sold 14,000 shares of the business’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $17.38, for a total value of $243,320.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.70% of the stock is owned by corporate insiders.
Several large investors have recently bought and sold shares of ENDP. Acrospire Investment Management LLC increased its stake in shares of Endo International PLC by 139.3% in the third quarter. Acrospire Investment Management LLC now owns 7,897 shares of the company’s stock valued at $159,000 after buying an additional 4,597 shares during the period. LS Investment Advisors LLC increased its stake in shares of Endo International PLC by 152.3% in the second quarter. LS Investment Advisors LLC now owns 13,661 shares of the company’s stock valued at $213,000 after buying an additional 8,247 shares during the period. IFP Advisors Inc increased its stake in shares of Endo International PLC by 103,542.9% in the second quarter. IFP Advisors Inc now owns 14,510 shares of the company’s stock valued at $226,000 after buying an additional 14,496 shares during the period. Bank of Hawaii bought a new stake in shares of Endo International PLC during the third quarter valued at $357,000. Finally, Icon Advisers Inc. Co. increased its stake in shares of Endo International PLC by 28.6% in the third quarter. Icon Advisers Inc. Co. now owns 18,000 shares of the company’s stock valued at $363,000 after buying an additional 4,000 shares during the period. Hedge funds and other institutional investors own 93.31% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.